Pancreatic Cancer Research

ResearcherWuhan UniversityActive in the last 2 years

Jianbo Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9493-694X; OpenAlex author ID A5011075675, A5128166090. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 16

  1. Mapping Genetic Regulation of Transcription to Identify Functional Variants and Genes Associated with Pancreatic Cancer Risk. Co-author DOI 10.1002/advs.202517184↗
  2. Author Correction: Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. First author DOI 10.1038/s41467-025-58613-9↗
  3. [Association and mechanism between genetic variants in binding region of pancreatic and duodenum homeobox-1 and susceptibility to pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112150-20250113-00031↗
  4. Risk SNP in a transcript of RP11-638I2.4 increases lncRNA-YY1 interaction and pancreatic cancer susceptibility. Co-author DOI 10.1007/s00204-023-03564-7↗
  5. Systematic analysis on expression quantitative trait loci identifies a novel regulatory variant in ring finger and WD repeat domain 3 associated with prognosis… Co-author DOI 10.1097/cm9.0000000000002180↗
  6. Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk. Co-author DOI 10.1158/0008-5472.can-21-4367↗
  7. Identification of genetic variants in m6A modification genes associated with pancreatic cancer risk in the Chinese population. Co-author DOI 10.1007/s00204-021-02978-5↗
  8. A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. First author DOI 10.1016/j.ejca.2021.04.008↗
  9. Evaluation of polymorphisms in microRNA-binding sites and pancreatic cancer risk in Chinese population. Co-author DOI 10.1111/jcmm.14906↗
  10. N6-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Co-author DOI 10.1136/gutjnl-2019-320179↗
  11. A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population. Co-author DOI 10.1002/cam4.2228↗
  12. A functional variant rs1537373 in 9p21.3 region is associated with pancreatic cancer risk. Co-author DOI 10.1002/mc.22968↗
  13. A functional variant in the boundary of a topological association domain is associated with pancreatic cancer risk. Co-author DOI 10.1002/mc.23077↗
  14. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. First author DOI 10.1038/s41467-018-06136-x↗
  15. BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population. Co-author DOI 10.18632/oncotarget.16422↗
  16. A single nucleotide polymorphism in the 3'-UTR of STAT3 regulates its expression and reduces risk of pancreatic cancer in a Chinese population. Co-author DOI 10.18632/oncotarget.11607↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoping Miao · 14 shared papers, 2016–2026 · strength 1.55
  2. Jiang Chang · 13 shared papers, 2016–2025 · strength 1.22
  3. Rong Zhong · 12 shared papers, 2016–2025 · strength 1.12
  4. Ying Zhu · 11 shared papers, 2016–2025 · strength 0.99
  5. Ying Zhu · 5 shared papers, 2022–2026 · strength 0.95
  6. Pingting Ying · 8 shared papers, 2019–2022 · strength 0.79
  7. Juntao Ke · 8 shared papers, 2016–2025 · strength 0.67
  8. Ming Zhang · 5 shared papers, 2019–2023 · strength 0.56
  9. W Tian · 1 shared paper, 2025 · strength 0.30
  10. Kun Huang · 3 shared papers, 2017–2025 · strength 0.30
  11. Beibei Zhu · 3 shared papers, 2016–2025 · strength 0.29
  12. Bo Li · 1 shared paper, 2026 · strength 0.25
  13. Xing Wang · 1 shared paper, 2026 · strength 0.25
  14. Shufang Mei · 3 shared papers, 2019–2020 · strength 0.24
  15. Ming Yang · 2 shared papers, 2018–2025 · strength 0.24
  16. Li Wang · 2 shared papers, 2018–2025 · strength 0.24
  17. Chen Hsuan Wu · 2 shared papers, 2018–2025 · strength 0.24
  18. Dongxin Lin · 2 shared papers, 2018–2025 · strength 0.24
  19. Bin Li · 2 shared papers, 2019–2021 · strength 0.17
  20. Zhiyong Yang · 1 shared paper, 2022 · strength 0.11
  21. Min Wang · 1 shared paper, 2022 · strength 0.11
  22. Beibei Zhu · 1 shared paper, 2019 · strength 0.08
  23. Xiaoping Miao · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.